Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2017-12-06
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety,
pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with
relapsed and refractory multiple myeloma.